TScan Therapeutics Secures Two FDA IND Clearances, Plans Phase 3 Trial for Lead Heme Candidate
TCRX is trading near its 52-week low of $0.882 (13% above the low).
Summary
TScan Therapeutics reported its fourth quarter and full year 2025 financial results, alongside a highly positive business update. The company announced FDA clearance for two new Investigational New Drug (IND) applications, TSC-102-A01 and TSC-102-A03, significantly expanding its heme malignancy program. Furthermore, TScan presented positive updated Phase 1 data for its lead candidate, TSC-101, which demonstrated favorable relapse-free and overall survival trends, and confirmed plans to initiate a pivotal Phase 3 trial for TSC-101 in the second quarter of 2026. For a clinical-stage biotechnology company with a modest market capitalization, securing multiple FDA IND clearances and advancing a lead program into a Phase 3 trial are critical de-risking events and strong catalysts. The company also reported sufficient cash to fund operations into the second half of 2027. Investors will be watching for initial data from Cohort C of the ALLOHA study and the launch of the pivotal trial in Q2 2026, as well as the initiation of the Phase 1 study for the newly cleared TSC-102 candidates in H2 2026.
At the time of this announcement, TCRX was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.7M. The 52-week trading range was $0.88 to $2.57. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.